Acidophil
4
11M
2
0.50
- Areas of investment
Summary
The venture was found in North America in United States. The main office of represented Corporate Investor is situated in the Baltimore.
The fund was created by Philip Goelet, Sydney Brenner MD PhD.
We can highlight the next thriving fund investment areas, such as Therapeutics, Biotechnology. Among the various public portfolio startups of the fund, we may underline Corridor Pharmaceuticals, AgriMetis For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. The fund has no exact preference in some founders of portfolio startups.
The fund is constantly included in less than 2 deals per year. Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2015.
The typical case for the fund is to invest in rounds with 5 participants. Despite the Acidophil, startups are often financed by Red Abbey Venture Partners, MedImmune Ventures, Syngenta Ventures. The meaningful sponsors for the fund in investment in the same round are Syngenta Ventures, Red Abbey Venture Partners, Quaker BioVentures. In the next rounds fund is usually obtained by Red Abbey Venture Partners, OUP (Osage University Partners), MedImmune Ventures.
Investments analytics
Analytics
- Total investments
- 4
- Lead investments
- 0
- Follow on index
- 0.50
- Investments by industry
- Biotechnology (4)
- Health Care (2)
- Therapeutics (2)
- Chemical (2)
- Agriculture (2)
- Investments by region
-
- United States (4)
- Peak activity year
- 2008
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Corridor Pharmaceuticals | 24 Jun 2010 | Biotechnology, Health Care, Therapeutics | Early Stage Venture | 13M | United States, Maryland, Towson |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.